James N Wilson (Director) sold ~$345K of Corcept Therapeutics
Scheduled in advanceTraded Jun 1, 2026 · Filed Jun 4, 2026
Corcept Therapeutics's See Remarks sold $278K of Corcept Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$278,103
Shares × reported transaction price
32 days after results of Apr 30, 2026, 58 days before results of Jul 29, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +11.2% | −2.5% | +13.7% |
| 30 days | +22.3% | −0.8% | +23.1% |
| 90 days | +47.5% | +1.1% | +46.4% |
Past results only. Not a forecast.
James N Wilson (Director) sold ~$345K of Corcept Therapeutics
Scheduled in advanceJames N Wilson (Director) sold ~$487K of Corcept Therapeutics
Scheduled in advanceTraded Jun 17 · filed 2 days laterNot under a reported trading plan
A Corcept Therapeutics director sold $1.69M of Corcept Therapeutics shares. The filing does not indicate a pre-arranged trading plan.